Unicycive Therapeutics, Inc. (UNCY)

NCM – Real vaqt narxi. Valyuta: USD

8.17

+0.22 (2.77%)

Yopilishda: May 12, 2026, 4:00 PM EDT

8.08

-0.09 (-1.10%)

Bozor oldidan: May 13, 2026, 7:46 AM EDT

12.05.2026

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update.

16.04.2026

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

09.04.2026

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.

09.04.2026

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET.

30.03.2026

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update.

06.03.2026

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - March 6, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.

17.02.2026

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Philadelphia, Pennsylvania--(Newsfile Corp. - February 17, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

09.04.2026

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

30.03.2026

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

06.03.2026

Unicycive Therapeutics, Inc. (UNCY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Videolar

No Data

Press-relizlar

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Videolar

No Data

Press-relizlar

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Search stocks

Unicycive Therapeutics, Inc. (UNCY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Videolar

No Data

Press-relizlar

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Videolar

No Data

Press-relizlar

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm